Currently, there is no cure for Refsum disease, but it is one of the few inherited retinal diseases and leukodystrophies that is highly treatable. The primary goal of treatment is to lower the levels of phytanic acid in the blood and tissues, which can halt the progression of many debilitating symptoms. Management requires a lifelong, multidisciplinary approach tailored to the individual's specific needs.
The foundational treatment for Refsum disease is a strict, low-phytanic acid diet. Because the body cannot metabolize this specific fatty acid, patients must avoid foods that contain it, primarily the meat and fat of ruminant animals (such as beef, lamb, and goat) and all dairy products. Adhering to this diet can significantly reduce phytanic acid levels, leading to the stabilization or even improvement of symptoms like peripheral neuropathy, ataxia (coordination issues), and ichthyosis (scaly skin). However, it is important to note that while the diet is highly effective for these symptoms, it may not fully stop the progression of vision loss (retinitis pigmentosa) or hearing loss.
In cases where dietary management alone is insufficient, or during acute crises where phytanic acid levels spike dangerously—often triggered by rapid weight loss, severe illness, or surgery—medical interventions such as plasmapheresis or lipid apheresis may be necessary. These procedures involve filtering the blood to physically remove the accumulated phytanic acid. Apheresis can rapidly lower toxic levels and is a critical tool in preventing severe complications, such as life-threatening cardiac arrhythmias.
Symptomatic treatments also play a crucial role in managing Refsum disease. Patients typically require regular monitoring by a cardiologist to detect and manage any heart rhythm abnormalities. Neurologists and physical therapists can assist with managing neuropathy and maintaining mobility. For vision and hearing loss, ophthalmologists and audiologists provide essential supportive care, including low-vision aids and hearing devices, to help maximize sensory function and independence.
Looking toward the future, the pipeline for Refsum disease therapies is promising. Researchers are actively exploring pharmacological treatments aimed at upregulating alternative metabolic pathways (such as omega-oxidation) to help the body clear phytanic acid more effectively. Additionally, gene therapy represents a significant frontier. By utilizing viral vectors to deliver functional copies of the defective PHYH gene into the patient's cells, scientists hope to restore the body's natural ability to metabolize phytanic acid. While these advanced therapies are currently in the preclinical or early clinical trial stages, they offer the potential for more definitive, long-lasting treatments.
Managing Refsum disease requires dedication and a coordinated healthcare team. Patients should maintain regular follow-ups with their specialists and consult their healthcare providers regarding any new symptoms or potential participation in clinical trials. With careful management, individuals can significantly alter the course of the disease and maintain a better quality of life.